Kala Pharmaceuticals Inc (KALA):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8086)
◆英語タイトル:Kala Pharmaceuticals Inc (KALA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8086
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:48
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company that offers nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase III clinical development for the treatment of post-surgical inflammation, meibomian gland disease, ocular inflammation, and dry eye disease. It also develops a small molecule receptor tyrosine kinase inhibitor (RTKi) program for the treatment of wet age-related macular degeneration (AMD). Kala Pharmaceuticals is funded by life science investors such as Lux Capital Management, Cam Capital, Longitude Capital Management, RA Capital Management, Third Rock Ventures and others. The company offers its products across the US. Kala Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.

Kala Pharmaceuticals Inc (KALA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Kala Pharma Raises USD68 Million in Series C Financing Round 11
Kala Pharma Raises USD7 Million in Venture Financing 13
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 14
Kala Pharma Raises US$11.5 Million In Series A Financing 16
Kala Pharma Raises US$6.2 Million In Seed Financing 18
Equity Offering 19
Kala Pharma Raises USD71.2 Million in Public Offering of Shares 19
Kala Pharma Raises USD103.5 Million in IPO 21
Kala Pharmaceuticals Inc – Key Competitors 23
Kala Pharmaceuticals Inc – Key Employees 24
Kala Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 09, 2018: Kala Pharmaceuticals reports second quarter 2018 financial results 26
Mar 26, 2018: Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 28
Nov 07, 2017: Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update 30
Corporate Communications 32
Mar 05, 2018: Kala Pharmaceuticals Names Gregory Perry As Board Director and as Audit Committee Chair 32
Nov 13, 2017: Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer 33
Oct 02, 2017: Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors 34
Product News 35
08/23/2018: Kala Pharmaceuticals announces FDA approval of INVELTYS for the treatment of post-operative inflammation and pain following ocular surgery 35
05/09/2018: Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch 37
01/05/2018: Kala Pharmaceuticals Announces New Drug Application For Inveltys (KPI-121 1%) Has Been Accepted For Review By The U.S. Food And Drug Administration 38
Product Approvals 39
Oct 25, 2017: Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYS (KPI-121 1%) 39
Clinical Trials 40
Jul 31, 2018: Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease 40
Jun 19, 2018: Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan 41
Apr 09, 2018: Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS 43
Jan 05, 2018: Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease 44
May 01, 2017: Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery 46
Jan 06, 2017: Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kala Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kala Pharma Raises USD68 Million in Series C Financing Round 11
Kala Pharma Raises USD7 Million in Venture Financing 13
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 14
Kala Pharma Raises US$11.5 Million In Series A Financing 16
Kala Pharma Raises US$6.2 Million In Seed Financing 18
Kala Pharma Raises USD71.2 Million in Public Offering of Shares 19
Kala Pharma Raises USD103.5 Million in IPO 21
Kala Pharmaceuticals Inc, Key Competitors 23
Kala Pharmaceuticals Inc, Key Employees 24
Kala Pharmaceuticals Inc, Other Locations 25

List of Figures
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Kala Pharmaceuticals Inc (KALA):製薬・医療:M&Aディール及び事業提携情報(Kala Pharmaceuticals Inc (KALA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆